NEWS | BEAM Alliance

NEWS

Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037

Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has received a Notice of Allowance from the United States Patent and Trademark Office for United States Patent Application Nos. 15/586,021 and 15/586,815.  The claims relate to the use of iclaprim to treat patients with bacterial infections, including but not limited to acute bacterial skin and skin structure infections, hospital-acquired bacterial pneumonia and Staphylococcus aureus lung infections in patients with cystic fibrosis.  The two method of use patents will expire in November 2037.

Full PR available here